Loading...
XLON
OPTI
Market cap8mUSD
Oct 09, Last price  
5.90GBP
1D
0.00%
1Q
-7.81%
Jan 2017
-90.33%
IPO
-99.81%
Name

OptiBiotix Health PLC

Chart & performance

D1W1MN
XLON:OPTI chart
P/E
—
P/S
5.23
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.15%
Rev. gr., 5y
-5.20%
Revenues
1m
+34.02%
000072,129161,5970028,200288,119191,073514,289744,8831,523,0002,213,000457,000644,000870,0001,166,000
Net income
-4m
L+115.51%
-54,972-32,000-16,000-36,000-1,163,000-1,653,000-1,632,000-811,000-1,281,000-1,298,0001,907,000-1,919,000-2,368,0005,802,0006,261,0002,587,000-2,039,000-1,805,000-3,890,000
CFO
-2m
L+0.11%
-27,000-65,000-42,000-1,076,200-376,789-706,243-983,464-1,246,066-1,753,241-1,233,548-1,723,248-927,963-1,564,661-1,109,000-1,527,000-1,768,000-1,770,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and tailored blends intended for integration into food products, nutritional supplements, and active ingredients. Their groundbreaking work aims to positively influence human physiology and yield substantial health benefits. Among its diverse product portfolio are Slimbiome, a natural ingredient for healthy and satiety-driven weight management, and SlimBiome Medical, a supplemental aid for weight control. Other offerings include CholBiome, a dietary supplement for maintaining healthy cholesterol; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health and overall well-being; LPGOS, a galactooligosaccharide utilized in food applications to mitigate cardiovascular risk factors and enhance general health; WellBiome, a functional fiber and mineral blend designed to bolster gut microbiome diversity and promote wellness; and Sweetbiotix, a sweetener for use in various foods and beverages. Ultimately, OptiBiotix's innovations are designed to prevent and manage prevalent chronic lifestyle diseases, including obesity, high cholesterol, and diabetes. The company was founded in 2012.

Key people

Non-Executive Chairman of the Board · since 2018
Stephen O'Hara
Chief Executive Officer, Executive Director · since 2015
Frederic Narbel
Executive Sales and Marketing Director · since 2019
Luis Gosalbez
Director of Business Development · since 2016
Sofia Kolyda
Director of Research and Development · since 2018
Co-Chairman of the Board · since 2015
Gareth Allan Barker
Non-Executive Director · since 2014
Non-Executive Director · since 2018
Jan Peter Fredrik Wennstrom
Non-Executive Director · since 2016
IPO date
Sep 09, 2011
Employees
9
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
Innovation Centre Innovation Way
Heslington
York YO10 5DG
GB
Previous name
DUCAT VENTURES PLC
Previous name
CERES MEDIA INTERNATIONAL PLC
Previous name
HARTFIELD SECURITIES PLC

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑112017‑112016‑11
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT